Debut Preloader

Debut is the future

We help the pharmaceutical and specialty chemical industries manufacture high value molecules by combining custom designed immobilized enzymes with continuous biomanufacturing processes. Our cell-free platform has the ability to transform low-value bio-renewable materials into high value therapeutics and specialty chemicals.

Combining the power of biocatalysis with continuous manufacturing will create a distinct change in how molecules are created. We believe our novel approaches, mindsets, and technology hold the key for addressing the largest problems in pharmaceutical and specialty chemical manufacturing.

When we look back in ten years it will be hard to remember what traditional chemical manufacturing looked like.

Why Debut?

Continuous manufacturing is changing the way we think about making molecules. We combine this revolutionary approach with novel enzymes and cells to change how we create chemicals.

01Benefit 1

We offer a range of high-value enzymes for biotherapeutic creation and modification.

02Benefit 2

We create novel immobilization for enzymes with high success rates.

03Benefit 3

We are committed to transforming how therapeutics and small molecules are made through continuous manufacturing combined with enzymes.

04Benefit 4

Debut removes the need for extensive R&D. We provide high value immobilized enzymes for use in continuous manufacturing systems.

Debut Team

Joshua Britton, PhD
Joshua Britton, PhD
Co-Founder and CEO
Brady Beauchamp
Brady Beauchamp
Co-Founder and COO
Gregory Weiss, PhD
Gregory Weiss, PhD
Co-Founder and Scientific Advisor
Nick Brideau, PhD
Nick Brideau, PhD
Director, Molecular Biology
Ali Emileh, PhD
Ali Emileh, PhD
Director, Protein Engineering
Megha Rawal
Megha Rawal
Research Associate II
Natalia Allos
Natalia Allos
Research Associate I
Enrique Cowen
Enrique Cowen
Research Associate I
Matt Hutcheson
Matt Hutcheson
Systems Engineer
bg

Specialty Enzyme SolutionsCombined With ContinuousManufacturing